The adequacy of NPS Pharmaceuticals Inc.’s risk management plan for Gattex (teduglutide) will be on the table at the FDA Gastrointestinal Drugs Advisory Committee’s Oct. 16 review of the short bowel syndrome drug.
FDA intends to ask the committee whether NPS’ proposed Risk Evaluation and Mitigation Strategy containing a communication plan is adequate...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?